Total Payments
$139,479
2024 Payments
$14,460
Companies
9
Transactions
58
Medicare Patients
2,520
Medicare Billing
$233,664
Payment Breakdown by Category
Consulting$58,798 (42.2%)
Research$44,500 (31.9%)
Other$28,750 (20.6%)
Travel$6,977 (5.0%)
Food & Beverage$454.32 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $58,798 | 16 | 42.2% |
| Unspecified | $44,500 | 17 | 31.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,250 | 9 | 16.7% |
| Travel and Lodging | $6,977 | 8 | 5.0% |
| Honoraria | $5,500 | 3 | 3.9% |
| Food and Beverage | $454.32 | 5 | 0.3% |
Payments by Type
General
$94,979
41 transactions
Research
$44,500
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $52,117 | 24 | $0 (2024) |
| Novartis Pharma AG | $23,311 | 10 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $23,164 | 3 | $0 (2021) |
| Genentech, Inc. | $16,113 | 11 | $0 (2022) |
| Apellis Pharmaceuticals, Inc. | $12,218 | 3 | $0 (2024) |
| Iridex Corporation | $5,500 | 3 | $0 (2022) |
| Daiichi Sankyo Inc. | $5,057 | 2 | $0 (2017) |
| Boehringer Ingelheim International GmbH | $1,000 | 1 | $0 (2020) |
| Carl Zeiss Meditec, Inc. | $1,000 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,460 | 5 | Apellis Pharmaceuticals, Inc. ($12,218) |
| 2023 | $13,605 | 5 | F. Hoffmann-La Roche AG ($13,605) |
| 2022 | $7,040 | 3 | Genentech, Inc. ($5,040) |
| 2021 | $17,832 | 6 | Novartis Pharma AG ($9,339) |
| 2020 | $25,639 | 9 | Novartis Pharmaceuticals Corporation ($13,169) |
| 2019 | $12,100 | 7 | Genentech, Inc. ($6,035) |
| 2018 | $16,759 | 10 | Novartis Pharma AG ($8,212) |
| 2017 | $32,043 | 13 | F. Hoffmann-La Roche AG ($17,727) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Consulting Fee | Cash or cash equivalent | $4,344.00 | General |
| Category: Ophthalmology | ||||||
| 08/30/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Consulting Fee | Cash or cash equivalent | $2,986.50 | General |
| Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,656.67 | Research |
| Study: Retinal vasculitis with or without retinal vascular occlusion among eyes with nAMD or DME treated with IVT agents as recorded in the Vestrum database | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $586.11 | Research |
| Study: Retinal vasculitis with or without retinal vascular occlusion among eyes with nAMD or DME treated with IVT agents as recorded in the Vestrum database | ||||||
| 03/29/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Consulting Fee | Cash or cash equivalent | $4,887.00 | General |
| Category: Ophthalmology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $8,272.00 | Research |
| Study: Clinical Outcomes of Patients With DME Presenting With ? 20/50 Visual Acuity Treated With Faricimab and Aflibercept in the YOSEMITE/RHINE Clinical Trials: A Pooled Subcohort Analysis | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,096.20 | Research |
| Study: VA2 PhIII Yosemite | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,041.11 | Research |
| Study: VA2 PhIII Yosemite | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,716.00 | Research |
| Study: An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $480.00 | Research |
| Study: VA2 PhIII Yosemite | ||||||
| 11/12/2022 | Genentech, Inc. | Lucentis (Biological) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Ophthalmology | ||||||
| 08/27/2022 | Genentech, Inc. | VABYSMO (Drug) | Consulting Fee | Cash or cash equivalent | $2,940.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 01/10/2022 | Iridex Corporation | — | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| 09/28/2021 | Novartis Pharma AG | BEOVU (Drug) | — | In-kind items and services | $1,357.14 | Research |
| Study: Publication support research related • Category: OPHTHALMOLOGY | ||||||
| 06/30/2021 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $1,548.00 | Research |
| Study: LUCENTIS DOSING RETREATMENT • Category: Ophthalmology | ||||||
| 06/15/2021 | Novartis Pharma AG | BEOVU (Drug) | Consulting Fee | Cash or cash equivalent | $5,375.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/02/2021 | Novartis Pharma AG | BEOVU (Drug) | — | In-kind items and services | $2,607.14 | Research |
| Study: Publication support research related • Category: OPHTHALMOLOGY | ||||||
| 04/24/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $5,375.00 | General |
| 02/20/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,570.00 | General |
| 11/12/2020 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 09/30/2020 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $1,574.00 | Research |
| Study: Lucentis Dosing Retreatment • Category: Ophthalmology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $680.00 | Research |
| Study: Anti-VEGF vascular endothelial growth factor Resistant Subretinal Fluid is Associated with Reduced Risk of Macular Atrophy and Better Visual Acuity Drug-Induced Choroidal New Vessel Homeostasis • Category: Ophthalmology | ||||||
| 07/29/2020 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $13,168.75 | Research |
| Study: OUTCOMES RESEARCH | ||||||
| 07/13/2020 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 06/30/2020 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $2,836.67 | Research |
| Study: Lucentis Dosing Retreatment • Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $13,169 | 1 |
| Lucentis Dosing Retreatment | F. Hoffmann-La Roche AG | $9,291 | 5 |
| Clinical Outcomes of Patients With DME Presenting With ? 20/50 Visual Acuity Treated With Faricimab and Aflibercept in the YOSEMITE/RHINE Clinical Trials: A Pooled Subcohort Analysis | F. Hoffmann-La Roche AG | $8,272 | 1 |
| Publication support research related | Novartis Pharma AG | $3,964 | 2 |
| An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD | F. Hoffmann-La Roche AG | $2,716 | 1 |
| VA2 PhIII Yosemite | F. Hoffmann-La Roche AG | $2,617 | 3 |
| Retinal vasculitis with or without retinal vascular occlusion among eyes with nAMD or DME treated with IVT agents as recorded in the Vestrum database | F. Hoffmann-La Roche AG | $2,243 | 2 |
| LUCENTIS DOSING RETREATMENT | F. Hoffmann-La Roche AG | $1,548 | 1 |
| Anti-VEGF vascular endothelial growth factor Resistant Subretinal Fluid is Associated with Reduced Risk of Macular Atrophy and Better Visual Acuity Drug-Induced Choroidal New Vessel Homeostasis | F. Hoffmann-La Roche AG | $680.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 662 | 1,591 | $672,095 | $64,088 |
| 2022 | 6 | 624 | 1,431 | $532,301 | $59,128 |
| 2021 | 6 | 634 | 1,488 | $464,133 | $62,519 |
| 2020 | 6 | 600 | 1,287 | $411,144 | $47,928 |
Total Patients
2,520
Total Services
5,797
Medicare Billing
$233,664
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 202 | 470 | $124,080 | $36,616 | 29.5% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Facility | 2023 | 204 | 471 | $82,425 | $8,789 | 10.7% |
| 92134 | Imaging of retina | Facility | 2023 | 190 | 439 | $251,986 | $8,561 | 3.4% |
| 67028 | Injection of drug into eye | Facility | 2023 | 31 | 111 | $173,604 | $7,914 | 4.6% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Facility | 2023 | 35 | 100 | $40,000 | $2,208 | 5.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 187 | 423 | $111,672 | $33,449 | 30.0% |
| 92134 | Imaging of retina | Facility | 2022 | 180 | 393 | $171,150 | $8,137 | 4.8% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Facility | 2022 | 194 | 428 | $74,900 | $8,080 | 10.8% |
| 67028 | Injection of drug into eye | Facility | 2022 | 20 | 86 | $134,504 | $6,353 | 4.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Facility | 2022 | 30 | 88 | $35,200 | $2,111 | 6.0% |
| 92004 | New patient complete exam of visual system | Facility | 2022 | 13 | 13 | $4,875 | $998.66 | 20.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 187 | 444 | $117,216 | $35,617 | 30.4% |
| 92134 | Diagnostic imaging of retina | Facility | 2021 | 179 | 411 | $102,750 | $8,809 | 8.6% |
| 92201 | Extended examination of eye with drawing of retina | Facility | 2021 | 196 | 442 | $77,350 | $8,521 | 11.0% |
| 67028 | Injection of drug into eye | Facility | 2021 | 20 | 78 | $121,992 | $5,887 | 4.8% |
| 76512 | Ultrasound of eye disease, growth, or structure | Facility | 2021 | 37 | 98 | $39,200 | $2,426 | 6.2% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Facility | 2021 | 15 | 15 | $5,625 | $1,260 | 22.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 132 | 233 | $61,512 | $15,966 | 26.0% |
| 92134 | Diagnostic imaging of retina | Facility | 2020 | 151 | 367 | $91,750 | $8,173 | 8.9% |
| 92201 | Extended examination of eye with drawing of retina | Facility | 2020 | 166 | 390 | $68,250 | $7,898 | 11.6% |
| 67028 | Injection of drug into eye | Facility | 2020 | 22 | 88 | $137,632 | $7,756 | 5.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 103 | 158 | $31,600 | $6,839 | 21.6% |
| 76512 | Ultrasound of eye disease, growth, or structure | Facility | 2020 | 26 | 51 | $20,400 | $1,296 | 6.4% |
About Marco Zarbin, MD, PHD
Marco Zarbin, MD, PHD is a Ophthalmology healthcare provider based in Newark, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376641423.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Marco Zarbin, MD, PHD has received a total of $139,479 in payments from pharmaceutical and medical device companies, with $14,460 received in 2024. These payments were reported across 58 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($58,798).
As a Medicare-enrolled provider, Zarbin has provided services to 2,520 Medicare beneficiaries, totaling 5,797 services with total Medicare billing of $233,664. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Newark, NJ
- Active Since 09/20/2006
- Last Updated 01/29/2026
- Taxonomy Code 207W00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1376641423
Products in Payments
- Lucentis (Biological) $42,903
- Syfovre (Drug) $12,218
- BEOVU (Drug) $9,339
- FTY (Drug) $8,212
- Gilenya (Drug) $5,760
- Non-Covered Product (Drug) $3,469
- VABYSMO (Drug) $2,940
- VISULAS 532s (Device) $1,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Newark
Robert Fechtner, Md, MD
Ophthalmology — Payments: $432,599
Ophthalmology $432,599
Dr. Albert Khouri, Md, MD
Ophthalmology — Payments: $394,020
Ophthalmology $394,020
Dr. David Chu, Md, MD
Ophthalmology — Payments: $177,269
Ophthalmology $177,269
Dr. Mark Law, Md, MD
Ophthalmology — Payments: $6,848
Ophthalmology $6,848
Dr. Roger Turbin, Md, MD
Ophthalmology — Payments: $5,303
Ophthalmology $5,303
Dr. Elliot Davidoff, Md, MD
Ophthalmology — Payments: $3,015
Ophthalmology $3,015